PDF herunterladen
CC BY-NC-ND 4.0 · Ibnosina Journal of Medicine and Biomedical Sciences 2019; 11(04): 196-203
DOI: 10.4103/ijmbs.ijmbs_69_19
Conference Highlights

Gulf X-linked hypophosphatemia preceptorship: July 4–6, 2019, Bicêtre Paris sud hospital, Paris, France

Hussain Alsaffar
1   Department of Paediatrics, Pediatric Endocrine and Diabetics Unit, Sultan Qaboos University Hospital, Muscat, Oman
2   Department of Paediatrics, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
,
Salem Beshyah
3   Department of Medicine, Dubai Medical College, Dubai
4   Department of Diabetes and Endocrinology, Mediclinic Airport Road Hospital, Abu Dhabi
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

X-linked hypophosphatemia (XLH) is an inherited disorder characterized by low levels of phosphate in the blood. Phosphate levels are low because phosphate is abnormally processed in the kidneys, which causes urinary phosphate wasting and leads to rickets in the young patients and osteomalacia in adults in addition to several other complications thereof. A 3-day conference was hosted by the Rare Diseases Unit of the Bicetre Paris Sud Hospital on July 4–6, 2019. Presentations covered the subject in a comprehensive manner spanning physiology, clinical presentations, disease burden, and the latest in the management of the XLH and its musculoskeletal, neurosurgical, obstetric, and other complications in both children and adults. Several illustrative and challenging cases were presented and discussed. The authors attended the event and would like to present a personal perspective to highlight the proceeding of the conference to extend the benefit to others who did not attend it.

Key-words:

Bone deformities - bone disorders - congenital and genetic diseases - endocrine diseases - fracture - kidney and urinary diseases - rickets - short stature - X-linked hypophosphatemia - X-linked hypophosphatemic rickets

Financial support and sponsorship

The program was fully funded by Kyowa Kirin Pharma FZ-LLC.




Publikationsverlauf

Eingereicht: 28. November 2019

Angenommen: 05. Dezember 2019

Artikel online veröffentlicht:
07. Juli 2022

© 2019. The Libyan Authority of Scientific Research and Technologyand the Libyan Biotechnology Research Center. All rights reserved. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License,permitting copying and reproductionso long as the original work is given appropriate credit. Contents may not be used for commercial purposes, oradapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Prié D, Ureña Torres P, Friedlander G. Latest findings in phosphate homeostasis. Kidney Int 2009;75:882-9.
  • 2 Kaneko I, Segawa H, Ikuta K, Hanazaki A, Fujii T, Tatsumi S, et al. Eldecalcitol Causes FGF23 resistance for pi reabsorption and improves rachitic bone phenotypes in the male hyp mouse. Endocrinology 2018;159:2741-58.
  • 3 Bonewald LF. The amazing osteocyte. J Bone Miner Res 2011;26:229-38.
  • 4 Bacchetta J, Bardet C, Prié D. Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting. Metabolism 2019. pii: S0026-0495(19)30021-6.
  • 5 Hernández-Frías O, Gil-Peña H, Pérez-Roldán JM, González-Sanchez S, Ariceta G, Chocrón S, et al. Risk of cardiovascular involvement in pediatric patients with X-linked hypophosphatemia. Pediatr Nephrol 2019;34:1077-86.
  • 6 Rowe PS. A unified model for bone-renal mineral and energy metabolism. Curr Opin Pharmacol 2015;22:64-71.
  • 7 Roizen JD, Li D, O'Lear L, Javaid MK, Shaw NJ, Ebeling PR, et al. CYP3A4 mutation causes Vitamin D-dependent rickets type 3. J Clin Invest 2018;128:1913-8.
  • 8 Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G, et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis 2019;14:58.
  • 9 Carpenter TO, Shaw NJ, Portale AA, Ward LM, Abrams SA, Pettifor JM. Rickets. Nat Rev Dis Primers 2017;3:17101.
  • 10 Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 2019;15:435-55.
  • 11 Mäkitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 2003;88:3591-7.
  • 12 Cagnoli M, Richter R, Böhm P, Knye K, Empting S, Mohnike K. Spontaneous growth and effect of early therapy with calcitriol and phosphate in X-linked Hypophosphatemic Rickets. Pediatr Endocrinol Rev 2017;15:119-22.
  • 13 Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-408.